SciFluor Life Sciences

Founded in 2011, SciFluor Life Sciences is based in Boston, US. The company specializes in creating small molecule therapeutic candidates.SciFluor Life Sciences focuses on developing innovative small molecule therapeutic candidates primarily targeting unmet medical needs in ophthalmology, fibrosis, and neurology. The company's lead product, SF0166, is specifically designed to treat retinal diseases such as Diabetic Macular Edema (DME) and wet Age-related Macular Degeneration (wet-AMD) through a topical eye drop formulation. SciFluor employs proprietary fluorine-based medicinal chemistry to enhance the potency, selectivity, and pharmacokinetic profiles of its products, which enables improved treatment outcomes. The company's expanding pipeline includes early-stage research initiatives in fibrosis and neurological disorders, showcasing its commitment to delivering novel therapeutic options.SciFluor Life Sciences generates revenue through partnerships and collaborations with various players in the biotechnology and pharmaceutical sectors. The company's transaction structure primarily consists of business-to-business (B2B) arrangements, where it supplies its innovative therapeutic candidates and associated services to research institutions and healthcare providers. Revenue is derived from licensing agreements, joint ventures, and potentially milestone payments linked to the clinical development of its products. Given the nature of the biotechnology sector, these transactions often involve negotiation of terms that align with the development phases of SciFluor's flagship products, such as SF0166. The company aims to expand its market presence in North America and Europe, with target timelines for market entry and product launches set for the next few years.

1. Series A

   May 17, 2011

   Amount

   $5M

   Investors

   Locked